Every material Form 8-K Cogent Biosciences, Inc. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cogent Biosciences reported third quarter 2026 results, with a net loss of $111.4 million compared with $80.9 million a year earlier. Higher general and administrative spending tied to commercial readiness for bezuclastinib drove most of the increase, and the filing reports no revenue line. The company said its $791.1 million cash balance is expected to fund operations into late 2028.
Net loss was $111.4 million for the quarter ended September 30, 2026, versus $80.9 million for the same period of 2025.
General and administrative expenses rose to $42.1 million from $14.4 million, mainly for commercial readiness ahead of a potential bezuclastinib launch.
Research and development expenses were $75.1 million, up from $69.0 million.
Cash, cash equivalents and marketable securities were $791.1 million as of September 30, 2026, versus $900.8 million at December 31, 2025 and $792.3 million at June 30, 2026.
Cogent Biosciences entered into a Commercial Supply Agreement dated September 1, 2026 with Hovione FarmaCiencia S.A. to manufacture bezuclastinib spray-dried dispersion and tablets. The agreement sets a five-year initial term with automatic two-year renewals, giving the company a defined manufacturing relationship for its product.
Agreement dated September 1, 2026 with Hovione FarmaCiencia S.A. for bezuclastinib spray-dried dispersion and tablets
Initial term of five years, followed by automatic two-year renewals
Company buys minimum percentages of its requirements from Hovione, with percentages decreasing over the term
Full agreement to be filed as an exhibit to the 10-Q for the quarter ending September 30, 2026, with some information omitted
Cogent Biosciences filed a prospectus supplement on August 10, 2026, covering the offer and sale of up to $400,000,000 of common stock through Guggenheim Securities under an existing sales agreement. The offering runs under an automatic shelf registration statement filed November 7, 2025, and the filing does not state a price or timing for any sales. For shareholders, this sets up a possible source of new shares that could dilute existing holdings if sold.
Up to $400,000,000 of common stock may be sold through Guggenheim Securities, as sales agent or principal, at market prices.
The prospectus supplement was filed August 10, 2026, under Form S-3ASR (File No. 333-291384).
Gibson, Dunn & Crutcher LLP issued a legal opinion on the shares (Exhibit 5.1).
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cogent Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →